Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy (Q36879127)

16 August 2017

1 reference

title

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy (English)

1 reference

16 August 2017

1 reference

I Craig Henderson

1

1 reference

PubMed ID

17627452

16 August 2017

Vinona Bhatia

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

919-943

1 reference

16 August 2017

7

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

16 August 2017

1 reference

Description of a short-term Taxol-induced nociceptive neuropathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Role of formulation vehicles in taxane pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

The dawning era of polymer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Paclitaxel and its formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Cure of myeloma: hype or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Transport of molecules across tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albuminin Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.7.919

21 January 2018

Identifiers

DOI

10.1586/14737140.7.7.919

1 reference

16 August 2017

1 reference

PubMed ID

17627452